Market Cap (In SEK)
145.8 Million
Revenue (In SEK)
1.01 Million
Net Income (In SEK)
-367.03 Million
Avg. Volume
823.87 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.2165-0.55
- PE
- -
- EPS
- -
- Beta Value
- 0.541
- ISIN
- SE0000722365
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.vivesto.com
- Ipo Date
- 2010-06-24
- Details
- Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
More Stocks
-
3843FreeBit Co., Ltd.
3843
-
WINSOMTXWinsome Textile Industries Limited
WINSOMTX
-
DIVSHKTDivyashakti Granites Limited
DIVSHKT
-
CIFRWCipher Mining Inc.
CIFRW
-
UEL
-
IDX
-
GLDS
-
PHRZFPharol, SGPS S.A.
PHRZF